Cardiogeni PLC
01 October 2026
1 October 2026
Cardiogeni PLC
("Cardiogeni" or the "Company")
Annual report update and temporary suspension from trading
Cardiogeni (AQSE: CGNI), a UK clinical stage biotechnology company founded by 2007 Nobel Laureate Sir Martin Evans to develop and commercialise novel heart regeneration medicines, announces that the publication of its audited annual accounts for the year ended 31 March 2026 will be delayed beyond 30 September 2026. This is due to auditor resourcing constraints, which led to the appointment of a new auditor, HaysMac, later in the process than usual.
As a result, trading in the Company's shares on the Aquis Stock Exchange Growth Market will be suspended with effect from 7.30 a.m. today, pending publication of the audited annual accounts.
The audit is progressing well and the Company expects to publish its audited annual accounts in the second half of October 2026, at which point it will seek restoration of trading, and will provide further updates as appropriate.
Contacts
|
Cardiogeni PLC |
|
|
Dr Darrin M Disley, Executive Chairman |
Via First Sentinel |
First Sentinel Corporate Finance Limited, Corporate Adviser |
|
|
Brian Stockbridge |
+44 020 3855 5551 |
|
SP Angel Corporate Finance LLP, Corporate Broker |
|
| David Hignell Vadim Alexandre Devik Mehta |
+44 20 3470 0470 |
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
ENDRNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.